Showing results (11-20 of 68) with videos related to

Sort By:
Pageof 7
Advances in Therapy|August 19, 2016
A Systematic Review and Network Meta-Analysis to Evaluate the Comparative Efficacy of Interventions for Unfit Patients with Chronic Lymphocytic LeukemiaNicolas Städler, Aijing Shang, Francesc Bosch, et al.
Clinical Lymphoma|March 30, 2005
Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disordersStephen A Johnson, Roger G Owen, David G Oscier, et al.
Clinical Hematology International|September 14, 2022
FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCLCaroline Dartigeas, Borhane Slama, Margaret Doyle, et al.
Future Oncology (London, England)|June 6, 2018
A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemiaConstantine S Tam, Veronique LeBlond, William Novotny, et al.
Leukemia & Lymphoma|November 5, 2013
A multicenter phase II study of single-agent enzastaurin in previously treated multiple myelomaEric Jourdan, Veronique Leblond, Hervé Maisonneuve, et al.
Cancer Chemotherapy and Pharmacology|March 11, 2006
Population pharmacokinetic study of methotrexate in patients with lymphoid malignancyDemiana William Faltaos, Jean Sebastian Hulot, Saïk Urien, et al.
Journal of Neuro-Oncology|December 21, 2010
Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred?Antonio Omuro, Luc Taillandier, Olivier Chinot, et al.
Blood|August 22, 2014
Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN studyGuillaume Cartron, Sophie de Guibert, Marie-Sarah Dilhuydy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2012
A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemiaIrene M Ghobrial, Philippe Moreau, Brianna Harris, et al.
Clinical Lymphoma & Myeloma|April 14, 2009
Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapyXavier Leleu, Jérome Tamburini, Aldo Roccaro, et al.
Pageof 7